Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Drug Delivery
    • Bioprocessing
    • Small Molecules
    • Cell and Gene
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Supply Chain
    • Regulation & Standards
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
    • eBooks
Subscribe
Subscribe
The Medicine Maker / Power List / 2018 / Business Captains / Ravi Nalliah

Ravi Nalliah

Co-Founder and Chief Executive Officer, TrakCel

  • Profile

Meet Ravi Nalliah

TrakCel is described as a clinical orchestration platform for regenerative and cell-based therapies. “As a passionate innovator working in a relatively conservative industry I thought that my passion would win over my colleagues when trying to create space for my companies to innovate. However, for innovation to flourish, passion can only get a leadership team so far. I now work hard to develop detailed cases for all activities so that my vision will appeal to all the personality types in my leadership team. TrakCel’s software is primarily used to support cell and gene therapy products. And it’s regrettable that, due to the complexity associated with the manufacture and administration of these products, the price tag tends to be high. But these treatments are curative, and I would like to see healthcare payers considering the accumulative reduction in healthcare costs once patients are treated with these therapies.”

False

Advertisement

Recommended

False

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.